tiprankstipranks
Pulmatrix reports Q3 EPS (71c) vs. ($1.03) last year
PremiumThe FlyPulmatrix reports Q3 EPS (71c) vs. ($1.03) last year
4M ago
Pulmatrix sees cash runway into 4Q26
Premium
The Fly
Pulmatrix sees cash runway into 4Q26
4M ago
Pulmatrix reports Q2 EPS ($1.59) vs. ($1.04) last year
Premium
The Fly
Pulmatrix reports Q2 EPS ($1.59) vs. ($1.04) last year
6M ago
Pulmatrix announces results from PUR3100 study
PremiumThe FlyPulmatrix announces results from PUR3100 study
9M ago
Pulmatrix Publishes Study on Inhalable Migraine Treatment
Premium
Company Announcements
Pulmatrix Publishes Study on Inhalable Migraine Treatment
9M ago
Pulmatrix reports Q1 EPS 23c vs ($1.22) last year
Premium
The Fly
Pulmatrix reports Q1 EPS 23c vs ($1.22) last year
10M ago
Pulmatrix’s IND application for PUR3100 to treat acute migraine accepted by FDA
PremiumThe FlyPulmatrix’s IND application for PUR3100 to treat acute migraine accepted by FDA
1y ago
Pulmatrix submits NDA to FDA to initiate Phase 2 trial of PUR3100
Premium
The Fly
Pulmatrix submits NDA to FDA to initiate Phase 2 trial of PUR3100
2y ago
Pulmatrix to present Phase 1 data of PUR3100 in acute migraine
Premium
The Fly
Pulmatrix to present Phase 1 data of PUR3100 in acute migraine
2y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100